Calvert Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-105,620
Closed -$6.17M 95
2016
Q4
$6.17M Sell
105,620
-1,285
-1% -$70.3K 0.23% 126
2016
Q3
$5.76M Buy
106,905
+5,864
+6% +$377K 0.21% 142
2016
Q2
$7.43M Buy
101,041
+3,356
+3% +$237K 0.3% 108
2016
Q1
$6.24M Buy
97,685
+4,435
+5% +$280K 0.28% 82
2015
Q4
$6.42M Buy
93,250
+18,003
+24% +$1.19M 0.29% 68
2015
Q3
$4.46M Sell
75,247
-85,708
-53% -$5.44M 0.22% 100
2015
Q2
$10.7M Buy
160,955
+50,004
+45% +$3.3M 0.47% 57
2015
Q1
$7.16M Buy
110,951
+9,970
+10% +$624K 0.46% 68
2014
Q4
$5.96M Buy
100,981
+5,776
+6% +$326K 0.41% 79
2014
Q3
$4.87M Buy
95,205
+48,073
+102% +$2.4M 0.36% 90
2014
Q2
$2.29M Buy
47,132
+791
+2% +$39K 0.15% 123
2014
Q1
$2.41M Buy
46,341
+7,894
+21% +$420K 0.17% 116
2013
Q4
$2.04M Buy
38,447
+1,221
+3% +$62.2K 0.15% 126
2013
Q3
$1.72M Sell
37,226
-955
-3% -$41.9K 0.21% 124
2013
Q2
$1.71M Buy
+38,181
New +$1.66M 0.23% 121

Other funds holding BMY

Calvert Investment Management's BMY Position: Q1 2017 in Review

Calvert Investment Management sold out of Bristol-Myers Squibb (BMY) in Q1 2017, closing a stake of 105,620 shares — an estimated $6.17M sold.

Calvert Investment Management first reported a position in BMY in Q2 2013 and held it in 15 quarters. The position peaked at $10.7M in Q2 2015. 1,597 funds tracked by Wall St. Rank hold BMY as of Q1 2017.

  • Calvert Investment Management reported no remaining Bristol-Myers Squibb position as of Q1 2017 after selling out during the quarter.
  • Calvert Investment Management sold 105,620 Bristol-Myers Squibb shares in Q1 2017, an estimated $6.17M.
  • Calvert Investment Management first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 15 quarters.
  • Calvert Investment Management's Bristol-Myers Squibb position peaked at $10.7M in Q2 2015.
  • 1,597 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.